Renal Cell Carcinoma
Conditions
Interventions
Experimental group:Iparomlimab and Tuvonralimab Injection+Axitinib+Selective Tumor Embolization
Sponsors
Tianjin Cancer Hospital Airport Hospita
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1 Age 18-80 years; 2 Histopathologically confirmed clear cell or non-clear cell renal carcinoma; 3 No prior systemic therapy received; 4 ECOG performance status score of 0 or 1; 5 Life expectancy 6 mon>=ths; 6 Voluntarily signed informed consent form.
Exclusion criteria
Exclusion criteria: 1?Inability to comply with the study protocol or procedures; 2?Patients with concurrent malignancies or severe organ dysfunction; 3?Presence of central nervous system (CNS) metastases; 4?Positive anti-HIV test; HBsAg-positive with HBV-DNA > upper limit of normal (ULN); active hepatitis C virus (HCV) infection (HCV RNA-positive); 5?Intolerance to radiotherapy or immunotherapy; 6?Chronic systemic corticosteroid therapy (>7 days) within 7 days prior to first dose; 7?Pregnancy or lactation; 8?Investigator-deemed ineligibility for study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, OS;Progression Free Survival, PFS; | — |
Countries
China
Contacts
Public Contactyangqing
Tianjin Cancer Hospital Airport Hospita
Outcome results
None listed